T Cells in Hematologic Malignancies: Biology, Microenvironment, and Therapeutic Advances

Dear Colleagues,

We are pleased to invite you to contribute to this Special Issue, “T Cells in Hematologic Malignancies: Biology, Microenvironment, and Therapeutic Advances.”

T cells are key regulators of immune surveillance and therapeutic response in hematologic malignancies. The clinical success of CAR-T cell therapies and bispecific T cell engagers has transformed the management of lymphoid malignancies and multiple myeloma, while revealing new challenges in understanding T cell biology within the unique bone marrow and lymphoid microenvironments. Emerging insights also point to important roles for T cells in myeloid neoplasms such as acute myeloid leukemia and myelodysplastic syndromes.

This Special Issue will highlight advances spanning basic mechanisms to translational and clinical applications. It welcomes original research and reviews on T cell biology, microenvironmental interactions, therapeutic innovation, and mechanisms of resistance. Research areas may include (but are not limited to) the following:

• T cell differentiation, exhaustion, and dysfunction in hematologic malignancies;
• The immune microenvironment of bone marrow and lymphoid tissues in liquid cancers;
• Mechanisms of immune escape, relapse, and resistance to immunotherapy;
• Biomarkers of T cell dysfunction and therapeutic response in hematologic malignancies;
• Next-generation CAR-T and T cell engagers/bispecific antibody therapies;
• Novel preclinical models and systems approaches.

By bringing together diverse perspectives, this Special Issue will highlight the unique challenges and opportunities of T cell immunology in hematology and chart future directions for therapeutic innovation

We look forward to receiving your contributions and to advancing the field together.

Maria Velegraki, MD, PhD
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.